

# Curriculum Vitae

## Dimitris Kardassis, PhD

Professor of Biochemistry, University of Crete Medical School

Affiliated faculty member, IMBB-FORTH, Heraklion Greece

Tel. +30-2810-394549, e-mail: [kardasis@uoc.gr](mailto:kardasis@uoc.gr); [kardasis@imbb.forth.gr](mailto:kardasis@imbb.forth.gr)

### *Undergraduate education*

**1985** B. Sc. in Biology, Department of Biology, Aristotelian University of Thessaloniki, Thessaloniki, Greece

**1991** Ph.D. in Biochemistry, Department of Biochemistry, Boston University Medical Center, Boston, MA, USA

PhD supervisor: Prof. Vassilis I. Zannis

Title of PhD thesis: "Transcriptional regulatory interactions between nuclear factors and DNA sequence elements on the promoter of the human apolipoprotein B gene"

### *Postdoctoral education*

1991-1992 Postdoctoral fellow, Section of Molecular Genetics, Whittaker Cardiovascular Institute, Boston University Medical School, Boston, MA, USA.

### *Academic Positions*

1993-1996	Research Associate, University of Crete Medical School
1996-1998	Adjunct Assistant Professor of Biochemistry, University of Crete Medical School
1998-	Assistant Professor of Biochemistry, University of Crete Medical School
1999-	Affiliated Faculty Member, Division of Gene Regulation and Epigenetics, Institute of Molecular Biology and Biotechnology, FORTH
2004-2008	Associate Professor of Biochemistry, University of Crete Medical School
2009-	Professor of Biochemistry, University of Crete Medical School

### *Fellowships*

1981-1985	Fellowship from the Foundation for National Fellowships (IKY)
1986-1991	Research Assistantship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center
1991-1992	Postdoctoral Fellowship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center
1994	EMBO Short Term Fellowship

### *Awards/Distinctions*

1999	Young Investigator Award, European Atherosclerosis Society
2004-	Fellow of the American Heart Association
2009-2010	Chairman of the Department of Basic Sciences, University of Crete Medical School

2010-2014	Election as Chair of COST Action BM0904 “HDL: from biological understanding to clinical exploitation”
2013-2017	Member of the Organizing Committee of the European Lipoprotein Club
2012-	Director of the Graduate Program “The Molecular Basis of Human Diseases” of the University of Crete Medical School
2017-2019	Elected member of the Board of Directors of the Hellenic Society of Biochemistry and Molecular Biology
2017-2018	Vice-Chair of the Working Group on “Pathophysiology of Atherosclerosis” of the Hellenic Society of Atherosclerosis
2019-2021	Chair of the Working Group on “Pathophysiology of Atherosclerosis” of the Hellenic Society of Atherosclerosis
2022-2026	Leader of Working Group 1 (Pathophysiological mechanisms in atherosclerosis) of COST Action CA21115 (AtheroNET)
2022-2026	Member of the general Assembly of MCSA-RISA CardioScope

### ***Teaching duties***

#### *Undergraduate courses*

Teaching in the following courses of the Department of Medicine of the University of Crete:  
 Biochemistry A (2nd semester): 30 hours of lectures (Course Coordinator)  
 Molecular Medicine (5th semester): 8 hours of lectures and 20 hours of student presentations (Course Coordinator)

#### *Graduate courses*

a) Graduate Program in Molecular Biology and Biomedicine (Departments of Medicine and Biology of the University of Crete) (<http://www.imbb.forth.gr/mbb/>)  
 Coordination of the graduate course “Molecular Biology of the gene”  
 Teaching in the graduate course “Molecular Biology of the cell”  
 Teaching in the graduate course “Multidisciplinary approach to understand and cure human diseases”  
 Coordination of the graduate course “Introduction to Research Methods”  
 Teaching in the graduate course: Molecular Biology of Cancer”  
 Coordination of the graduate course “Molecular Organization of Life”  
 Teaching in the graduate course “Cellular Organization of Life”  
 Teaching in the graduate course “Organization and processing of biological information”  
 b) Graduate Program “The Molecular Basis of Human Diseases (MBHD)” (Department of Medicine of the University of Crete) (<http://www.grad-mbhd-uoc.gr>)  
 Coordinator of the graduate course MBNA-101 “Introduction to molecular medicine and basic principles of research methodology”  
 Instructor in the graduate course MBNA-103 “Cardiovascular and Metabolic Diseases”.

### ***Reviewer for the following Journals***

PLoS One; European Journal of Pharmacology; Translational Research; Atherosclerosis; Atherosclerosis, Thrombosis and Vascular Biology; Scientific Reports; Journal of Immunological Sciences; Oncogene; Nucleic Acids Research; BBA; Biochemistry-USA; Journal of Biological Chemistry; Circulation Research; Current Medicinal Chemistry; Cancer Management and Research; Archives of Medical Science; Journal of Cellular and Molecular Medicine; Translational Research; American Journal of Physiology-Endocrinology and Metabolism; Peertechz Journal of Biological Research and Development; OncoTargets and Therapy; Journal of Biomedical Research; Arthritis

Research & Therapy; Cell and Tissue Research; Cellular Physiology and Biochemistry; Metabolism.

### **Editorial Board**

Associate Editor: Atherosclerosis Plus (<https://www.journals.elsevier.com/atherosclerosis-plus> )

Member of the Editorial Board: Cells (<https://www.mdpi.com/journal/cells>),

Member of the Editorial Board: Receptors (<https://www.mdpi.com/journal/receptors>)

### **Books**

“High Density Lipoproteins: From Biological Understanding to Clinical Exploitation” Arnold von Eckardstein and Dimitris Kardassis Editors, Handbook of Experimental Pharmacology Vol. 224 Springer Open, 2015.

### **Invited presentations (2012-2023)**

1. Invited speaker at the International Workshop on HDL and cardiovascular risk: potential for intervention, Biarritz, France June 13<sup>th</sup>, 2012. Title of presentation: *Transcriptional regulation of HDL*.
2. Invited speaker at the EAS Satellite Symposium “High Density Lipoproteins: From basic science to therapeutic advances”, Milano Italy, May 28-29, 2012. Title of presentation: *Mechanisms of ABCA1 gene regulation in the liver*
3. Invited speaker at the 1st Summer School on HDL in Groningen The Netherlands, August 30-September 1, 2012. Title of presentation: *Regulation of HDL metabolism*.
4. Invited speaker at the 1<sup>st</sup> Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2012. Title of presentations. 1) *Transcriptional regulation of genes involved in lipoprotein metabolism*, 2) *The molecular and genetic basis of atherosclerosis*, 3) *HDL: From biological understanding to clinical exploitation*
5. Invited speaker at the 1<sup>st</sup> Postgraduate Symposium in Translational Medicine of WHBA, Ioannina, February 22-24, 2013. Title of Presentations: 1) *Lipoprotein and atherosclerosis: evolving concepts*, 2) *High Density Lipoproteins: Metabolism, genetics and regulation*.
6. Invited speaker at the 2nd Summer School on “HDL: Physiology, regulation and therapeutic potential”, Bucharest-Sinaia Romania, August 26-30, 2013. Title of presentation: *Transcriptional regulation of genes involved in HDL metabolism*.
7. Invited speaker at the 81st Congress of the European Atherosclerosis Society, Lyon France Spain, June 2-5, 2013. Title of presentation: *Genetic and non-genetic factors affecting HDL levels and functions*.
8. Invited speaker that the 3rd Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2014. Title of presentations. 1) *Regulation of genes involved in lipoprotein metabolism*, 2) *The molecular and genetic basis of atherosclerosis* 3) *HDL, inflammation and atherosclerosis: Understanding lipoprotein metabolism using animal models*.
9. Invited speaker at the 11th World Hellenic Biomedical Congress - Clinical & Translational Medicine, Itylo Greece, May 21, 2014. Title of presentation: *The role of High Density Lipoprotein Genes in Cardiovascular Disease*
10. Invited speaker at the 3rd Hellenic Forum For Science, Technology & Innovation “MEDICINE FOR THE FUTURE”, Athens Greece, June 29-July 3, 2015. Title of the presentation: *Dyslipidemia, Atherogenesis and Chronic Inflammatory Diseases: Lessons from animal models*
11. Invited speaker at the 7<sup>th</sup> Annual Symposium of the Hellenic Atherosclerosis Society, Athens December 1-2, 2017. Title of presentation: *“New genes and miRNAs that are associated with the Metabolic Syndrome in humans and in mouse models”*.

12. Invited speaker at the 2<sup>nd</sup> COST Action CardioRNA Meeting, Lisbon February 13-15, 2019. Title of presentation: *“Changes in hepatic transcriptome and circulating miRNAs in a mouse model of metabolic syndrome”*.
13. Invited speaker at the Annual Conference of the Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease, Athens October 3-5, 2019. Title of presentation: *“Understanding the pathogenesis of metabolic diseases using genomics approaches”*.
14. Invited speaker at the 40<sup>th</sup> Anniversary Symposium of the Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest, September 19-20, 2019. Title of presentation: *“Identification of new genes and miRNAs that are implicated in the pathogenesis of the Metabolic Syndrome in mice: a transcriptomics approach”*
15. Invited speaker at the 1st COST Action AtheroNET Meeting, Bucharest March 22-24, 2023. Title of the presentation: “New developments in metabolic diseases: lessons from animal models”
16. Invited speaker at the Annual Conference of the Hellenic Society of Atherosclerosis, Athens December 1-3, 2023. Title of the presentation: “Dyslipidemia and rheumatoid arthritis: New data from animal models”

### ***Organization of international meetings/workshops***

<b>Year</b>	<b>Meeting/Workshop organised</b>
2003	Member of the organizing committee of the EMBO Workshop "Liver gene expression in health and disease" that was held in Lygaria Crete, June 14-18, 2003.
2004	Member of the organizing committee of the "2004 Post-Olympic HDL Workshop" Heraklion Crete, September 1-4, 2004.
2011	Organizer and Chair of the International Workshop on HDL “HDL: from biological understanding to clinical practice”, Athens Greece, January 30, 2011.
2012	Organizer and Chair of the 2 <sup>nd</sup> International Conference of COST BM0904 in Barcelona, Spain, January 26-27, 2012
2012	Co-organizer of the EAS Satellite Symposium “High Density Lipoproteins: From basic science to therapeutic advances”, Milano Italy, May 28-29, 2012.
2012	Organizer and Co-Chair of the Joint COST/NSFA International Workshop “HDL and cardiovascular risk: potential for intervention” Biarritz France, June 13, 2012.
2012	Member of the organizing committee of the 63 <sup>rd</sup> Annual Conference of the Hellenic Society of Biochemistry and Molecular Biology, Heraklion Greece November 9-11, 2012.
2012	Organizer of the 1 <sup>st</sup> Summer School on HDL in Groningen The Netherlands, August 30-September 1, 2012
2013	Member of the Scientific Board of the 1 <sup>st</sup> Postgraduate Symposium in Translational Medicine of WHBA, Ioannin Grece February 22-24, 2013.
2013	Co-organizer of the 2 <sup>nd</sup> Summer School on “HDL: Physiology, regulation and therapeutic potential”, Bucharest-Sinaia Romania, August 26-30, 2013
2014	Member of the Scientific Board of the 3rd Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2014.
2013-17	Member of the Organizing Committees of the 36 <sup>th</sup> , 37 <sup>th</sup> , 38 <sup>th</sup> , 39 <sup>th</sup> and 40 <sup>th</sup> scientific meetings of the European Lipoprotein Club (ELC) in Tutzing, Germany, 2013-2017.
2016	Member of the scientific committee of the 84 <sup>th</sup> Congress of the European Atherosclerosis Society in Innsbruck, Austria May 29 <sup>th</sup> – June 1 <sup>st</sup> 2016.
2018	Member of the Scientific Committee of the 1 <sup>st</sup> Olympiad in Cardiovascular Medicine, International Symposium on Experimental & Clinical Cardiovascular Medicine Athens,

May 17<sup>th</sup>-19<sup>th</sup> 2018.

2022 Member of the Organizing Committee of the 2nd Olympiad in Cardiovascular Medicine, International Symposium on Experimental & Clinical Cardiology, Heraklion, April 27-30, 2022.

***Major contributions to the early careers of excellent researchers***

<b>Name of researcher</b>	<b>Affiliation</b>	<b>Current position</b>
Kalliopi Liadaki	MSc student	Assistant Professor of Biochemistry, University of Thessaly, Greece
Pelagia Vorgia	MSc student	Assistant Professor of Pediatrics, University of Crete, Greece
Costas Drosatos	MSc student,	Assistant Professor, Temple University, USA
Giorgos Koukos	MSc student,	Senior Scientific Researcher, Scientist, Genenotech, USA
Giorgos Koutsodontis	MSc/PhD student	Molecular Biologist at Metaxa Cancer Hospital, Piraeus, Greece
Vassiliki Prokova	MSc/PhD student	Brand Manager in Hematology, Abbvie Pharmaceuticals, Greece
Ioanna Mosialou	MSc/PhD student	Assistant Professor, Columbia University, USA
Ioanna Tiniakou	MSc/PhD student	Post-doctoral fellow, NYU, USA
Panagiotis Fotakis	MSc/PhD student	Scientist 2, Immunology at Dren Bio, Inc. San Francisco, USA
Eleftheria Vasilaki	MSc/PhD student	Post-doctoral fellow, Ludwig Institute for Cancer Research, Sweden
Efstathia Thymiakou	MSc/PhD student	Post-doctoral fellow, University of Crete, Greece
Andreas Kateifidis	MSc/PhD student	Sr. Business Operations Analyst, Process Management & Business Analytics, Vertex Pharmaceuticals, USA
Dimitris Nasias	PhD student	Post-doctoral fellow, NYU, NY, USA
Dimitris Theofilatos	MSc/PhD student	Post-doctoral fellow, U of North Carolina at Chapel Hill, USA

***Funding (2006-2026)***

2006-2008	Program “PENED-2003” funded by the Greek Ministry of Research and Technology: Coordinator: <b>D. Kardassis</b> . “Transcriptional regulation of genes involved in the biogenesis and catabolism of HDL: New approaches to increase plasma HDL levels”, 210.000 €
2007-2009	Sixth Framework Program-Health-STREP. Funded by EU. Coordinator: <b>A. von Eckardstein (Switzerland)</b> Partners: V. Zannis, <b>D. Kardassis (Greece)</b> . “Functional genomics of inborn errors and therapeutic interventions in high density lipoprotein (HDL) metabolism”. Budget for the team: 420.000 €.
2011-2014	Program “SYNERGASIA 09” funded by the General Secretariat for Research and Technology of Hellas “Targeted strategies for new therapies of Cardiovascular and Inflammatory Diseases based on the atheroprotective functions of HDL”. <b>Coordinator: D. Kardassis</b> . Patners: A. Chroni (Demokritos), D. Boumpas (Ucrete), Abbott Hellas 500.000 €
2010-2013	Program “HRAKLEITOS II” funded by the Greek Ministry of Education. <b>Coordinator: D. Kardassis</b> . PhD candidate: P. Fotakis. “Proteins that regulated HDL levels and functions”. 45.000 €

2010-2014	COST Action BM0904: “HDL- From Biological Understanding to Clinical Exploitation”. Funded by EU/ESF. <b>Chair: D. Kardassis (Greece)</b> . Participants from 15 European countries. 100.000 €year
2012-2015	Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Structure/function, regulation and genetic variation of High Density Lipoproteins: Novel biomarkers and therapies for patients with Coronary Artery Disease”. <b>Coordinator: D. Kardassis</b> . Total budget: 520.000 €. Budget for the team: 200.000 €.
2012-2015	Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Cell cycle variations: comparing the stem cell and cancer cell life cycles”. Coordinator: Z. Lygerou. <b>Coordinator of the University of Crete team: D. Kardassis</b> . Total budget: 520.000 Euros. Budget for the team: 160.000 €
2012-2014	Cooperation between Greece and Romania in Science and Technology funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. <b>Coordinator: D. Kardassis (Greece)</b> . Romanian partner: Prof. M. Simionescu (Bucharest). Title: Prospects for novel therapies of Cardiovascular Diseases that are based on the transcriptional regulation of the apoE gene. 15.000 €.
2014-2016	Research Program ARISTEIA II funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “High Density Lipoproteins in the intersection of diabetes, inflammation and cardiovascular disease”. Coordinator: <b>D. Kardassis</b> . Total budget: 210.000 Euros.
2013-2018	“RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol”. Funded by EU FP7-HEALTH-2012-INNOVATION-1 program. Integrated Project. Chair: B. Groen (Netherlands). <b>Partner: D. Kardassis (Greece)</b> 750.000 €
2015-2017	IKY-SIEMENS Research grants: “The role of TGFβ and small Rho GTPases in carcinogenesis and stem cell differentiation. <b>Coordinator: D. Kardassis</b> . 15.500 €
2020-2022	Research Program “INNOVATION-CYCLE II” funded by the General Secretariat for Research and Technology of Hellas. Title: “New therapies aiming to improve the atheroprotective and immunomodulatory properties of high density lipoprotein (HDL) for the treatment of autoimmune and cardiovascular diseases”. Coordinator: A. Chroni; Partner: <b>D. Kardassis</b> . Budget for the team: 250.000 €
2024-2026	Research Program “Funding Projects in Leading-Edge Sectors – RRFQ: Basic Research Financing (Horizontal support for all Sciences)” funded by the Hellenic Foundation for Research and Innovation. Title: “Elucidating the impact of apolipoprotein E and metabolic comorbidities on the pathogenesis of Alzheimer’s Disease (APOE-META-BRAIN)”. Coordinator: <b>D. Kardassis</b> . Budget for the team: 250.000 €

### ***Recent Publications (2020-2025)***

1. Axiotis I, Kakale A, Lazaridou D, Dedemadi AG, Chroni A, Multescu M, Gafencu AV, Tzardi M, and **Kardassis D**. (2025) Hypertriglyceridemia impairs HDL functionality, promotes macrophage metabolic activation and exacerbates antigen-induced rheumatoid arthritis in mice which can be reversed by fenofibrate treatment. *Biochim Biophys Acta Mol Cell Biol Lipids*. 1870(8):159686.
2. Mitić T, Georgescu A, Alexandru-Moise N, Davies MJ, Vindis C, Novella S, Gerdtts E, Kararigas G, Wettinger SB, Formosa MM, Kwak BR, Molica F, Amigo N, Caporali A, de la Cuesta F, Hall IF, Chroni A, Martelli F, Schmid JA, Magni P, and **Kardassis D**. (2025) Current status and challenges of multi-omics research using animal models of atherosclerosis. *J Mol Cell Cardiol Plus*. 10;13:100476.
3. Nordestgaard LT, Wulford BN, de Gonzalo-Calvo D, Sopić M, Devaux Y, Matic L, Wettinger SB, Schmid JA, Amigó N, Masana L, Catapano AL, **Kardassis D**, Magni P; EU-AtheroNET COST Action CA21153. (2025) ultimomics in atherosclerotic cardiovascular disease. *Atherosclerosis*. 408:120414.
4. Dedemadi AG, Sevdali E, Georgiadou D, Valanti EK, Neofotistou-Themeli E, Chanis T, Goutakoli P, Thymiakou E, Drakos E, Christopoulou G, Bournazos S, Constantoulakis P, Verginis P, **Kardassis D**, Stratikos E, Sidiropoulos P, Chroni A. (2025) Dantrolene is an HDL-associated paraoxonase-1 activator with immunosuppressive and atheroprotective properties. *Biochim Biophys Acta Mol Cell Biol Lipids*. 1870(2):159596. doi: 10.1016/j.bbalip.2025.159596.
5. **Kardassis D**, Vindis C, Stancu CS, Toma L, Gafencu AV, Georgescu A, Alexandru-Moise N, Molica F, Kwak BR, Burlacu A, Hall IF, Butoi E, Magni P, Wu J, Novella S, Gamon LF, Davies MJ, Caporali A, de la Cuesta F, Mitić T. (2025) Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. *Vascul Pharmacol*. 158:107452. doi: 10.1016/j.vph.2024.107452.
6. Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S, Kontaraki J, Kalomoirakis P, Kanoupakis E, Patrianakos A, Papadomanolakis A, Daskalaki E, Kiouisi T, Kouraki K, Kranioti E, Tzardi M, Venihaki M, Karagogeos D, Capetanaki Y, **Kardassis D**, Kochiadakis G, Parthenakis F, Marketou M. (2024) Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy. *Cells*. 9;13(16):1328. doi: 10.3390/cells13161328.
7. Acharya S, Preda MB, Papatheodorou I, Palioura D, Giardoglou P, Tsata V, Erceg S, Barbalata T, Ben-Aicha S, Martino F, Nicastro L, Lazou A, Beis D, Martelli F, Sopic M, Emanuelli C, **Kardassis D**, Devaux Y. (2023) EU-CardioRNA COST Action CA17129.. The science behind soft skills: Do's and Don'ts for early career researchers and beyond. A review paper from the EU-CardioRNA COST Action CA17129. *Open Res Eur*. 3:55. doi: 10.12688/openreseurope.15746.2.
8. Sopić M, Karaduzovic-Hadziabdic K, **Kardassis D**, Maegdefessel L, Martelli F, Meerson A, Munjas J, Niculescu L, Stoll M, Magni P, and Devaux Y. (2023) Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. *Journal of Molecular and Cellular Cardiology Plus*. 6:100048. <https://doi.org/10.1016/j.jmccpl.2023.100048>.
9. Thymiakou E, Tzardi M, and **Kardassis D**. (2023) Impaired hepatic glucose metabolism and liver- $\alpha$ -cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4 $\alpha$  (Hnf4a) gene. *Metabolism*. 139:155371. doi: 10.1016/j.metabol.2022.155371.
10. Dalakoura-Karagkouni K, Tiniakou I, Zannis VI, and **Kardassis D**. (2022) Using adenovirus-mediated gene transfer to study the effect of myeloperoxidase on plasma lipid levels, HDL structure

and functionality in mice expressing human apoA-I forms. *Biochem Biophys Res Commun.* 622:108-114. doi: 10.1016/j.bbrc.2022.07.001.

11. Thymiakou E, Xenikaki E, and **Kardassis D.** (2022) Intestine-specific ablation of the Hepatocyte Nuclear Factor 4a (Hnf4a) gene in mice has minimal impact on serum lipids and ileum gene expression profile due to upregulation of its paralog Hnf4g. *Biochim Biophys Acta Mol Cell Biol Lipids.* 1867(3):159108. doi: 10.1016/j.bbalip.2021.159108.

12. Valanti EK, Dalakoura-Karagkouni K, Fotakis P, Vafiadaki E, Mantzoros CS, Chroni A, Zannis V, **Kardassis D,** and Sanoudou D. (2022) Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. *Metabolism.* 127:154954. doi: 10.1016/j.metabol.2021.154954.

13. **Kardassis D,** Thymiakou E, and Chroni A. (2022) Genetics and regulation of HDL metabolism. *Biochim Biophys Acta Mol Cell Biol Lipids.* 1867(1):159060. doi: 10.1016/j.bbalip.2021.159060.

14. Valanti EK, Dalakoura-Karagkouni K, Siasos G, **Kardassis D,** Eliopoulos AG, and Sanoudou D. (2021) Advances in biological therapies for dyslipidemias and atherosclerosis. *Metabolism.* 116:154461. doi: 10.1016/j.metabol.2020.154461 (review).

15. Chroni A, Rallidis L, Vassou D, Gkolfinopoulou C, Papakosta P, Zervou MI, Goulielmos GN, Kiouri E, Pappa D, Eliopoulos E, and **Kardassis D.** (2020) Identification and characterization of a rare variant in apolipoprotein A-IV, p.(V336M), and evaluation of HDL functionality in a Greek cohort with extreme HDL cholesterol levels. *Arch Biochem Biophys.* 696:108655. doi:10.1016/j.abb.2020.108655.

16. Nasias D, Dalakoura-Karagkouni K, Vassou D, Papagiannakis G, Papadaki A, and **Kardassis D.** (2020) Transcriptome analysis of the adipose tissue in a mouse model of metabolic syndrome identifies gene signatures related to disease pathogenesis. *Genomics.* 112(6):4053-4062. doi: 10.1016/j.ygeno.2020.06.053.

17. Thymiakou E, Othman A, Hornemann T, and **Kardassis D.** (2020) Defects in High Density Lipoprotein metabolism and hepatic steatosis in mice with liver-specific ablation of Hepatocyte Nuclear Factor 4A. *Metabolism.* 110:154307. doi: 10.1016/j.metabol.2020.154307.

**Total number of publications: 124**

<https://www.ncbi.nlm.nih.gov/myncbi/167kjj4puoski/bibliography/public/>